In the current scenario, diabetes is known as one of the world’s fastest-spreading chronic diseases all across the globe. The diabetic population has witnessed an exponential rise with an equal proliferation in its diagnostics and treatment sector. The very common causes such as the change in lifestyle, unhealthy eating habits, genetics of patients, and reduced physical activities, to name a few, have led to increased obese population, which is the major cause of type 2 diabetes in adults. The increasing prevalence, health burden as well as cost of this chronic disease have altogether accelerated the global interest within the innovative care models that deploy approaches such as community-based care coupled with information technology to enhance or transform the prevention of diseases, diagnosis, and treatment.
With the upsurge in the populace suffering from diabetes all over the globe, various government organizations and pharmacies are joining forces to develop innovative products so as to address the global patient population. The merging of the healthcare and information technology vertical has led to the development of such medical aids which have the potential to cure this disease in a more. In this lead, the researchers of Stanford University have come up with a major breakthrough concerning the insulin formation and its relevant favorable consequences. A new insulin formulation is under the research process that begins to be functional right after the injection, which otherwise do take a substantial time to work. This prompt kind of formulation potentially work four times faster as compared to the existing fast-acting insulin preparations available for commercial use.
This breakthrough is a result of synchronized efforts of the researchers on the purported monomeric insulin. This focal point- insulin – possess a molecular composition which, as per the theory, would allow this to function faster as compared to the other forms of insulin. The catch is that this form of insulin is quite volatile when it comes to its practical utility. Thus, in order to comprehend the ultrafast ability of this monomeric insulin, the research has counted on a few ‘materials science magic’. Hence, following the testing and screening of a large sets of additive polymers, the scientists successfully discovered a polymer that could fixate this volatile kind of insulin for more than 24 hours in stressed conditions. This took the research to a more successful phase which is expected to bring the ultrafast insulin to a more commercialized platform.
